Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2025
0mins
Source: Globenewswire
MGX-0024 Field Study Results: Mangoceuticals, Inc. announced successful results from field studies of its antiviral compound MGX-0024, which demonstrated 100% survival in chickens against respiratory diseases, significantly reducing mortality compared to untreated farms.
Market and Regulatory Plans: The company is scaling production and seeking regulatory approvals for MGX-0024 in various countries, aiming to provide an antibiotic-free solution for poultry health while addressing global antibiotic restrictions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
